North America:

  • Live Nation nears settlement with U.S. DOJ over antitrust case, retaining Ticketmaster with concessions and $200 million in damages.
  • Bristol-Myers Squibb reports positive Phase III results for mezigdomide in multiple myeloma.
  • Starboard Value urges Lamb Weston to enhance operations and review international portfolio for share price boost.
  • Amazon Pharmacy expands access to Eli Lilly's Zepbound KwikPen for weight management.
  • Pfizer advances eczema drug tilrekimig to Phase 3 trials after successful Phase 2 study.
  • Microsoft announces Wave 3 of Microsoft 365 Copilot with new features and pricing tiers.

Europe:

  • Novo Nordisk partners with Hims & Hers Health to sell Wegovy and Ozempic, resolving legal dispute.
  • Helen plans €1bn-€5bn investment in Small Modular Reactor capacity for power demand and CO2 reduction.
  • ABB partners with Nvidia to enhance robot training with Omniverse simulation data.
  • GEA Group reports 7.5% rise in 2025 net profit, raises dividend, targets organic revenue growth.
  • ZAGA Capital Partners raises €210 million for German Real Asset Opportunities II fund.
  • GSK licenses liver disease drug linerixibat to Alfasigma for up to $690 million.
  • Generali sells Irish operations to Zurich for €337 million, improving Solvency II ratio.
  • M&C Saatchi announces CEO resignation, appoints interim executive chair, launches GBP 4.5 million share buyback.
  • AstraZeneca secures priority FDA review for breast-cancer drug Enhertu.

Rest of World:

  • HUTCHMED (China) Ltd withdraws oncology drug TAZVERIK in China, no financial impact expected.
  • Saudi Aramco issues rare oil tenders to mitigate Middle East export disruptions.
  • Vestas plans nacelle assembly plant in Japan by fiscal 2029 for cost reduction and wind expansion.
  • Santos commits to Moomba Central Optimization Project for cost savings and efficiency.
  • Merafe Resources reports 72% drop in profit due to idled ferrochrome smelters.
  • CATL reports 57.1% increase in Q4 net profit, exceeding expectations.
  • Shenzhen's Longgang district supports OpenClaw AI ecosystem amid data access concerns.
  • Tencent re-engages in Paramount-Warner Bros deal with new funding.
  • Railtel Corporation of India Ltd declares a dividend of 1 rupee per share.
  • Nexperia China achieves small-batch production of 12-inch wafer devices amid disputes.